Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Blanke

Showing results (71-80 of 190) with videos related to

Pageof 19
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practicesP W T Pisters, C D Blanke, M von Mehren, et al.
The Oncologist|November 19, 2015
S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal TumorsCharles D Blanke, Cathy Rankin, Christopher Corless, et al.
Journal of the National Cancer Institute|April 24, 2018
A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group StudiesPatricia A Deverka, Rick Bangs, Karma Kreizenbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumorsGeorge D Demetri, Yanfeng Wang, Elisabeth Wehrle, et al.
JAMA Network Open|May 1, 2020
Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive FindingsJoseph M Unger, Charles D Blanke, Michael LeBlanc, et al.
Seminars in Radiation Oncology|April 21, 1999
Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancerC D Blanke, H Choy, M Teng, et al.
Blood|April 9, 2004
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinibPetri Bono, Andreas Krause, Margaret von Mehren, et al.
Clinical Colorectal Cancer|August 24, 2011
Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysisDaniel J Renouf, Howard J Lim, Caroline Speers, et al.
JAMA Network Open|August 10, 2019
Trends in Medical Aid in Dying in Oregon and WashingtonLuai Al Rabadi, Michael LeBlanc, Taylor Bucy, et al.
Journal of Surgical Oncology|June 26, 2024
Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?Thomas L Sutton, Kevin G Billingsley, Alicia J Johnson, et al.
Pageof 19

Showing results (71-80 of 190) with videos related to

Sort By:
Pageof 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practicesP W T Pisters, C D Blanke, M von Mehren, et al.
The Oncologist|November 19, 2015
S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal TumorsCharles D Blanke, Cathy Rankin, Christopher Corless, et al.
Journal of the National Cancer Institute|April 24, 2018
A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group StudiesPatricia A Deverka, Rick Bangs, Karma Kreizenbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumorsGeorge D Demetri, Yanfeng Wang, Elisabeth Wehrle, et al.
JAMA Network Open|May 1, 2020
Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive FindingsJoseph M Unger, Charles D Blanke, Michael LeBlanc, et al.
Seminars in Radiation Oncology|April 21, 1999
Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancerC D Blanke, H Choy, M Teng, et al.
Blood|April 9, 2004
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinibPetri Bono, Andreas Krause, Margaret von Mehren, et al.
Clinical Colorectal Cancer|August 24, 2011
Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysisDaniel J Renouf, Howard J Lim, Caroline Speers, et al.
JAMA Network Open|August 10, 2019
Trends in Medical Aid in Dying in Oregon and WashingtonLuai Al Rabadi, Michael LeBlanc, Taylor Bucy, et al.
Journal of Surgical Oncology|June 26, 2024
Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?Thomas L Sutton, Kevin G Billingsley, Alicia J Johnson, et al.
Pageof 19